BULGARI
23.5.2022 09:40:10 CEST | Business Wire | Press release
In the presence of Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture and Arts Authority (Dubai Culture) and Member of the Dubai Council, Bulgari, the leading Italian brand in the world of jewellery and luxury, and in partnership with Dubai Culture, announced the winner of the first edition of the Bulgari Contemporary Art Award during a ceremony held at the Italy Pavilion at Expo 2020 Dubai. The winner was chosen from a shortlist of three art pieces selected by the award’s jury.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005313/en/
The ceremony was attended by His Excellency Giuseppe Finocchiaro, Consul-General, Italian Consulate (Dubai); Paolo Glisenti, Italy’s Commissioner General for Expo 2020 Dubai; Jean Christophe Babin, Group CEO of Bulgari; Lucia Boscaini, Brand Curator at Bulgari; Her Excellency Hala Badri, Director General of Dubai Culture; and Dr Saeed Mubarak bin Kharbash, CEO of the Arts and Literature Sector at Dubai Culture .
A panel of three experts — Giuseppe Moscatello, Nujoom Alghanem and Patricia Millns FRSA — visited the exhibition held from 3 to 8 February at the Van de Goudenberg Art Gallery in the Dubai International Financial Centre to celebrate the participating works. Among the 15 artworks, the committee shortlisted three artists: Juma AlHaj (UAE), Dubai-based Kamal Alzubi (Jordan), and Dubai-based artist Nima Nabavi (Iranian-American), who the jury selected for the winning artwork.
Nima Nabavi received a trophy that celebrates the aesthetic and cultural dialogue between Rome and Dubai by combining a silhouette inspired by Bulgari’s iconic doorways and storefronts with architectural ornaments inspired from Dubai’s Al Fahidi and Al Shindagha Historical Neighbourhoods. The trophy was designed by Emirati designer Kamla AlOlama and produced by Asateer, an Emirati studio founded by Mohammed AlSuwaidi specialising in contemporary products that reflect the rich Emirati heritage.
The trophy uses materials with great cultural significance. A frame is fabricated from the rich woods of the UAE’s national tree, Al Ghaf, an emblem of heritage and perseverance. The design also incorporates native mother-of-pearl inlaid motifs and brass.
Nima Nabavi expressed his happiness at winning the award and thanked Bulgari and Dubai Culture for giving him the opportunity to share his artistic vision. He also extended his gratitude to the experts and jury for selecting his work for the award.
The winning artwork was exhibited at the Italy Pavilion in Expo 2020. The artist was also offered the opportunity to experience Rome through the eyes of Bulgari as part of a week-long journey through the brand’s universe. He will experience the beauty of Bulgari’s colourful gems and visit the DomvsAvrea museum space in the Maison’s flagship store in Rome, as well as attend workshops with Bulgari designers and exclusive tours of historical sites and cultural locations particularly linked with Bulgari’s patronage, initiatives and inspiration. In addition, the winning piece will be exhibited at venues associated with Dubai Culture and Bulgari, according to a pre-defined schedule.
Launched in July 2021, the Bulgari Contemporary Art Award opened the door for UAE national and resident artists to submit artworks under the theme ‘Beauty Connects People’ that had them creatively express how beauty connects people and how cities like Dubai and Rome are linked by their inspirational beauty and innovation.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom